Bone Cell Growth Regulation by Runx2/Cbfa1

$357,750R01FY2012ARNIH

Mayo Clinic Rochester, Rochester MN

Investigators

Linked publications & trials

Paper 38873024 Paper 38851465 Paper 38341164 Paper 38321966 Paper 37706312 Paper 37693373 Paper 37593409 Paper 37572850 Paper 37558192 Paper 37530724 Paper 37493605 Paper 37182560 Paper 36909335 Paper 36538650 Paper 36250949 Paper 36202795 Paper 36191822 Paper 35922466 Paper 35194136 Paper 35093449 Paper 34864007 Paper 34700039 Paper 34619722 Paper 34292968 Paper 34238359 Paper 34144503 Paper 33969529 Paper 33940225 Paper 33859343 Paper 33853680 Paper 33816122 Paper 33737193 Paper 33593128 Paper 33234056 Paper 33218968 Paper 33213041 Paper 32976998 Paper 32693629 Paper 32686190 Paper 32657816 Paper 32579261 Paper 32353583 Paper 32332097 Paper 32145378 Paper 32086861 Paper 32022326 Paper 31777278 Paper 31696354 Paper 31648392 Paper 31579953 Paper 31494240 Paper 31424116 Paper 31176732 Paper 31176730 Paper 30977555 Paper 30849542 Paper 30784215 Paper 30327434 Paper 30321475 Paper 30248488 Paper 29933019 Paper 29923217 Paper 29914885 Paper 29899112 Paper 29882479 Paper 29868646 Paper 29860023 Paper 29775757 Paper 29388702 Paper 29285799 Paper 29280310 Paper 29227558 Paper 29212250 Paper 29174847 Paper 29076267 Paper 29040138 Paper 28671282 Paper 28618870 Paper 28537529 Paper 28371128 Paper 28370561 Paper 28331585 Paper 28297568 Paper 28178884 Paper 28132772 Paper 28130552 Paper 28008373 Paper 27862226 Paper 27798372 Paper 27758858 Paper 27738322 Paper 27585950 Paper 27515308 Paper 27507649 Paper 27378743 Paper 27324965 Paper 27229140 Paper 27216774 Paper 26909883 Paper 26826615

Abstract

DESCRIPTION (provided by applicant): Skeletal regenerative medicine promises to mitigate age-related bone loss and support fracture healing but requires manipulation of biological properties of osteogenic progenitor cells. Osteogenic cells must sustain their phenotype during lineage-expansion yet undergo a number of mitotic cell cycles to generate the requisite number of cells for proper tissue-organization. The proposed study will examine fundamental mechanisms that ensure cells retain a post-mitotic molecular memory of the bone phenotype. The central hypothesis of our study is that key mRNAs for osteogenic factors are passed on to daughter cells during mitosis as a component of a non-genomic epigenetic mechanism and that selected microRNAs (miRs) attenuate the translation of these transmitted mRNAs. Our hypothesis is based on a robust set of preliminary data showing that the osteogenic master regulator Runx2 is controlled by mitotic miRs in osteoblastic cell lines. Based on these and other preliminary data, we will (i) characterize mitotic mRNAs and cognate miRs that suppress expression of lineage-specific factors in osteogenic cells, (ii) examine miR dependent changes in protein expression and lineage-plasticity in proliferating osteoblasts, and (iii) characterize the physiological role of mitosis-related miRs during skeletal development in vivo. Validation of this concept would (i) establish a major new dimension in cell cycle regulation, (ii) reveal a previously unrecognized function for miRs during mitosis, (iii) define a novel molecular mechanism for biological control of gene expression in lineage-committed cells, and (iv) identify specific miRs that are transmitted to osteogenic progeny cells upon mitosis ('mito-miRs'). From a molecular therapeutic perspective, these miRs permit generation of epigenomic agents that control cellular inheritance by targeting cell fate determining factors which mediate mesenchymal stem cell expansion and differentiation.

View original record on NIH RePORTER →